Overview
XLO market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
- O
- 8.21
- H
- 8.65
- L
- 8.21
- C
- 8.65
- Vol
- 844.00
Daily history from Oct 22, 2021
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $8.21
- Previous Close
- $8.71
- Day High
- $8.65
- Day Low
- $8.21
- 52 Week High
- $11.73
- 52 Week Low
- $6.65
- 7 Day Return
- +7.99%
- 30 Day Return
- -2.09%
- 90 Day Return
- -5.98%
- 1 Year Return
- -24.19%
- Daily Notional Volume
- $7.3K Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$4.19 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.13 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -34.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $6.47 – $12.32 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $56.4M · P/B 0.95 · P/S 0.88.